ININFA   02677
INSTITUTO DE INVESTIGACIONES FARMACOLOGICAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Interaction between the fibroblast growth factor 2 (FGF2) and the progesterone receptor (PR) pathways in breast cancer
Autor/es:
FIGUEROA VIRGINIA; LAMB CAROLINE; LANARI CLAUDIA; SAHORES ANA
Lugar:
Mar del Plata, Buenos Aires
Reunión:
Congreso; LXI Reunión Científica anual de la Sociedad Argentina de Investigación Clínica; 2016
Institución organizadora:
SAIC
Resumen:
About 75% of all breast cancers express hormone receptors and these patients are eligible to receive endocrine therapy. However, some patients are unresponsive or develop resistance to hormone therapy. Dysregulation of the FGF2/FGFR signaling pathway has been associated with different types of cancer. In humans, FGF2 consists of five protein isoforms with different molecular weights: 18 kDa (low molecular weight, LMW-FGF2) and 22, 22.5, 24 and 34 kDa (high molecular weight, HMW-FGF2). In murine and human breast cancer models, we demonstrated that tumor variants which are resistant to the antiprogestin mifepristone (MFP), express a lower PR isoform A/isoform B ratio compared to responsive tumors. We recently observed that hormone resistant variants also express higher levels of HMW-FGF2.